CroatiaThe weight-loss medication Wegovy, produced by Danish pharmaceutical company Novo Nordisk, has become available in German pharmacies since Tuesday. It requires a prescription and is approved for adults with a body mass index (BMI) of 30 or higher, or those with overweight and a related condition like type 2 diabetes. Patients currently cover the costs of tablets and injections themselves. The German Pharmacists' Association does not expect a lasting surge in demand for the tablets, noting that initial data from England suggests a much higher dropout rate compared to injections. Wegovy is already available in the United States, United Kingdom, UAE, and Bahrain, where demand has been very high. Common side effects include nausea, vomiting, and dizziness, similar to the injectable form. Strict rules apply for taking the medication, including fasting before and after consumption. Doctors must assess suitability, dosage, and potential interactions before prescribing.
Bias read (Center): The article presents factual information about the availability and usage of Wegovy in Germany without overtly favoring any political stance. It provides balanced reporting on the medication’s approval process, cost implications, and medical considerations, without emphasizing ideological positions.
